Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Multiple Myeloma
Interventions: MyHOPE™ for Multiple Myeloma, MyHope HCP Portal; Device
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 34
States / cities: Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 27 more

Conditions: Infra Renal Aortic Aneurysm
Interventions: Not listed
Lead sponsor: Simbionix US Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Miami, Florida • Tampa, Florida • Teaneck, New Jersey + 2 more

Conditions: Smoking
Interventions: THS 2.2 Menthol (mTHS 2.2), Menthol Conventional Cigarette (mCC), Smoking Abstinence (SA); Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 22 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions: Odronextamab multiple dose levels; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 10
States / cities: Orange, California • Stanford, California • Tampa, Florida + 4 more

Conditions: Hypertension
Interventions: LFF269, Eplerenone, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 11
States / cities: Anaheim, California • Fort Myers, Florida • Miramar, Florida + 7 more

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy; Biological · Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 64
States / cities: Birmingham, Alabama • Covina, California • La Palma, California + 49 more

Conditions: Advanced Solid Tumors
Interventions: PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 3
States / cities: New York, New York • Portland, Oregon • Houston, Texas

Conditions: Major Depressive Disorder
Interventions: Agomelatine (AGO178C), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 43
States / cities: Birmingham, Alabama • Costa Mesa, California • El Centro, California + 39 more

Conditions: Hypoactive Sexual Desire Disorder
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 60
States / cities: Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more

Conditions: Chronic Periodontitis
Interventions: LANAP; Device
Lead sponsor: Institute for Advanced Laser Dentistry; Other
Eligibility: 25 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Schizophrenia
Interventions: Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System; Device
Lead sponsor: ERP Biomarker Qualification Consortium; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Garden Grove, California • Torrance, California • Marlton, New Jersey + 1 more

Conditions: Pure Autonomic Failure, Multiple System Atrophy
Interventions: Magnetic Resonance Spectroscopy Imaging; Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Asthma
Interventions: Fluticasone furoate 50mcg, Fluticasone propionate 100mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Los Angeles, California • Rolling Hills Estates, California • Sacramento, California + 17 more

Conditions: Rotator Cuff Syndrome
Interventions: InSpace sub-acromial tissue spacer system, Partial repair of rotator cuff; Device · Procedure
Lead sponsor: OrthoSpace Ltd.; Industry
Eligibility: 40 Years to 100 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 18
States / cities: Van Nuys, California • Denver, Colorado • Fort Lauderdale, Florida + 12 more

Conditions: Triple Negative Breast Cancer
Interventions: GTx-024; Drug
Lead sponsor: GTx; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Fort Lauderdale, Florida • Lakeland, Florida • Miami, Florida + 4 more

Conditions: Central Visual Impairment, Macular Degeneration
Interventions: Training visual sensitivity, Combination training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Dry Eye Syndrome
Interventions: cis-UCA ophthalmic solution 1.0%, cis-UCA ophthalmic solution 2.5%, Placebo ophthalmic solution; Drug
Lead sponsor: Herantis Pharma Plc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Cardiovascular Disease and Lipoprotein(a)
Interventions: Blood draw for Lp(a); Diagnostic Test
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 49,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 180
States / cities: Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 150 more

Conditions: Small Cell Lung Cancer
Interventions: Durvalumab, Tremelimumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 34
States / cities: Tucson, Arizona • Santa Rosa, California • New Haven, Connecticut + 30 more

Conditions: Kidney Diseases
Interventions: DM199; Drug
Lead sponsor: DiaMedica Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Mesa, Arizona • Granada Hills, California • Los Angeles, California + 11 more

Conditions: Geographic Atrophy
Interventions: APL-2, Sham Procedure; Drug · Other
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 67
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more

Conditions: Bardet-Biedl Syndrome, POMC Deficiency
Interventions: Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg, Setmelanotide 20 mg, Setmelanotide 25 mg, Setmelanotide 30 mg; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Scottsdale, Arizona • Marshfield, Wisconsin

Conditions: Head and Neck Cancer, Human Papilloma Virus
Interventions: MEDI0457, CELLECTRA®5P device, Durvalumab; Drug · Device
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 14
States / cities: San Francisco, California • Orlando, Florida • Atlanta, Georgia + 10 more

Conditions: Glaucoma and Ocular Hypertension
Interventions: ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR; Drug
Lead sponsor: Envisia Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more

Search by objective public record fields.

A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM

Patient-Specific Simulation Used for EVAR Procedure Rehearsal - Evaluation of Clinical Performance With and Without Prior Rehearsal

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Study to Compare Laser Assisted New Attachment Procedure (LANAP) to Traditional Treatments of Chronic Periodontitis

Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects

Magnetic Resonance Spectroscopy in Autonomic Failure

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

A Pivotal Study to Assess the InSpace™ Device for Treatment of Full Thickness Massive Rotator Cuff Tears

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

Factors in Learning And Plasticity: Macular Degeneration

Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma